All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your PsOPsA Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL hub

ALL hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB and Bristol Myers Squibb: For educational content and news updates.

Disease AreasTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2023-10-10T10:31:43.000Z

EADV 2023: Top abstracts in psoriasis and psoriatic arthritis

By Ella Dixon
Oct 10, 2023
Share:

To help navigate the exciting content being presented at the European Academy of Dermatology and venerology (EADV) 2023 Congress, we have provided recommendations for the top abstracts to look out for in psoriasis and psoriatic arthritis.

Psoriasis

6624

 

Efficacy and safety of ME3183 administered orally in subjects with moderate to severe plaque psoriasis: A multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 2a study

1732

Effect of high-dose subcutaneous spesolimab on skin manifestations: Results from the pivotal Effisayil 2 trial of flare prevention in generalized pustular psoriasis

3364

Deucravacitinib significantly improves symptoms and signs of psoriasis in patients with moderate to severe psoriasis: Results from the phase 3 POETYK PSO-1 and POETYK PSO-2 trials

4506

A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: Efficacy of Overall and Scalp Psoriasis Responses from FRONTIER 1

3536

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, improves outcomes in plaque, generalized pustular, and erythrodermic psoriasis in Japan: results from the POETYK PSO-4 study

 

 

Psoriatic arthritis

2959

Bimekizumab efficacy and safety in patients with active psoriatic arthritis and psoriasis: 52-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies

1204

Long-term Efficacy of Guselkumab on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologicnaïve Patients With Psoriatic Arthritis

3319

Ixekizumab significantly improved quality of life and joint pain in patients with psoriatic arthritis, nail disease and DIP Involvement from SPIRIT-H2H

4041

Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 148-Week Results from the KEEPsAKE 2 Trial

4887

Early Oligoarticular Psoriatic Arthritis Responds to Treatment With Apremilast: Week 16 Results From FOREMOST – a Phase 4 Randomized Controlled Trial

EADV 2023 abstracts

To download this document, click below.

Download here

More about...
EADV 2023PsoriasisPsoriatic arthritis

Your opinion matters

HCPs, what is your preferred format for educational content on the PsOPsA Hub?
11 votes - 44 days left ...

Related articles

Add bookmark

BE OPTIMAL and BE COMPLETE: 52-week post-hoc analysis of patients with BSA ≥3% and ≥10%

During the EADV 2023 Congress, Thaçi presented a post-hoc analysis of two phase III trials, BE OPTIMAL and BE COMPLETE, of bimekizumab in patients with PsA.

Nov 28, 2023
Add bookmark

BE OPTIMAL and BE COMPLETE: 52-week post-hoc analysis of patients with BSA ≥3% and ≥10%

During the EADV 2023 Congress, Thaçi presented a post-hoc analysis of two phase III trials, BE OPTIMAL and BE...

Nov 28, 2023
Add bookmark

Utilization of teledermatology in a post-COVID-19 era: Recommendations from the IPC

The IPC have developed a telemedicine working group with the purpose of formulating a ‘call to action’ for use of telemedicine in patients with psoriasis. Here, we...

Apr 6, 2023
Add bookmark

Utilization of teledermatology in a post-COVID-19 era: Recommendations from the IPC

The IPC have developed a telemedicine working group with the purpose of formulating a ‘call to action’ for use of...

Apr 6, 2023

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox